Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 5
Submit an article Journal homepage
203
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma

Vadim IvanovDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France; Correspondence[email protected]
,
Laure FarnaultDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France;
,
Cedric MercierDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France;
,
Cecile ColavolpeDepartment of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France;
,
Geoffroy VentonDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France; ;INSERM, Marseille, France;
,
Julien ColleDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France;
,
Hubert LepidiDepartment of Pathology, CHU La Conception, AP-HM, Marseille, France;
,
Isabelle ArnouxDepartment of Hematology, CHU La Timone, AP-HM, Marseille, France;
,
Corinne Nicolino-BrunetDepartment of Hematology and Vascular Biology, CHU La Conception, AP-HM, Marseille, France;
,
Yael Berda-HaddadDepartment of Hematology and Vascular Biology, CHU La Conception, AP-HM, Marseille, France;
,
Raphaelle FanciullinoPharmacy Unit, La Conception, University Hospital of Marseille, APHM, Marseille, France; ;SMARTc Unit, Pharmacokinetics Laboratory, Marseille, France;
,
Gleb IvanovSurrey and Sussex NHS Trust, Redhill, UK
&
Regis CostelloDepartment of Hematology, La Conception, University Hospital of Marseille, Marseille, France; ;INSERM, Marseille, France;
show all
Pages 1230-1233 | Received 27 Sep 2019, Accepted 09 Dec 2019, Published online: 03 Jan 2020

References

  • Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
  • Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858–865.
  • Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3(16):2491–2498.
  • Goebeler M-E, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–1111.
  • Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416.
  • Hijazi Y, Klinger M, Kratzer A, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-Hodgkin lymphoma. Curr Clin Pharmacol. 2018;13(1):55–64.
  • Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
  • Baxter LT, Zhu H, Mackensen DG, et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517–1528.
  • Demosthenous C, Lalayanni C, Iskas M, et al. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Curr Probl Cancer. 2019;43(3):222–227.
  • Goldberg SL, Mangan KF, Klumpp TR, et al. Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant. 1994;14(1):180–181.
  • Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996;88(1):41–48.
  • Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100.
  • Han P, Story C, McDonald T, et al. Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. Cytotherapy. 2002;4(2):165–175.
  • Khan MW, Gul Z. Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant. Clin Case Rep. 2016;4(8):743–746.
  • Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2019;94(2):257–265.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.